Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

Apellis Pharmaceuticals (APLS) shares rose 3.2% after securing a capped royalty deal with Sobi, receiving up to $300 million, including $275 million upfront cash and potential $25 million in milestones, for 90% of its future ex-U.S. royalties from Aspaveli. This transaction significantly strengthens Apellis' balance sheet and enhances operational flexibility, particularly as the company awaits FDA and EU decisions on label expansion for pegcetacoplan (Aspaveli/Empaveli) in two rare kidney diseases, C3G and IC-MPGN, following positive Phase III results. The capital infusion is notable given APLS shares have declined 44% year-to-date.

Analysis

Apellis Pharmaceuticals has executed a strategic transaction to bolster its financial position, securing up to $300 million by monetizing 90% of its future ex-U.S. royalties for Aspaveli in a capped deal with Sobi. The immediate $275 million cash infusion substantially strengthens its balance sheet, adding to the $358.4 million in cash and securities held at the end of Q1 2025 and providing critical operational flexibility. This financial de-risking comes at a pivotal moment, with key regulatory decisions pending for the label expansion of its drug pegcetacoplan. The U.S. FDA is set to decide by July 28, 2025, on its use for two rare kidney diseases, supported by positive Phase III VALIANT study data that demonstrated a statistically significant 68% reduction in proteinuria. Despite this positive corporate action, which prompted a 3.2% share price increase, the stock remains down 44% year-to-date, drastically underperforming the industry's 3.4% decline and holding a Zacks Rank of #4 (Sell), indicating that underlying market concerns persist beyond immediate liquidity.

Key Decisions for Investors

• The upfront cash payment of $275 million significantly de-risks the company's balance sheet, mitigating concerns about near-term cash burn or dilutive financing ahead of crucial regulatory milestones.
• Investors should focus on the upcoming FDA Priority Review decision on July 28, 2025, for pegcetacoplan, as a positive outcome based on strong Phase III data is the primary catalyst that could reverse the stock's severe year-to-date underperformance.
• While the royalty deal is a strategic positive, the stock's 44% year-to-date decline and the existing Zacks #4 (Sell) rating suggest caution is warranted, as these factors may indicate persistent underlying risks not fully addressed by this transaction.
• For long-term valuation models, it is crucial to factor in that Apellis will regain 100% of the ex-U.S. royalties after Sobi reaches its performance-based cap, preserving the drug's long-term value for the company.